CClinicalTrials.gg
Sign In
CompletedNCT07807007CP006-ASTHMAUpdated Sep 8, 2026

Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

A Phase 2 interventional study of Budesonide, Formoterol Fumarate, and Umeclidinium Bromide and Budesonide, Formoterol Fumarate, and Umeclidinium Bromide in Asthma, sponsored by Shanghai Xin Huanghe Pharmaceutical Co., Ltd.. Completed at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Shanghai Xin Huanghe Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate whether two different doses of an investigational drug (CP006 Inhalation Powder, a triple combination of budesonide, formoterol, and umeclidinium) improve lung function in adults with asthma compared to an active comparator (budesonide/formoterol inhalation powder, a marketed two-component product).

The main questions it aims to answer are:

Does CP006 produce a greater change in lung function (measured by trough FEV₁ before morning dose) after 28 days of treatment compared to the comparator? What medical problems do participants experience when taking CP006? Researchers will compare two dose levels of CP006 against the active comparator in a 1:1:1 ratio.

Participants will:

Complete a screening visit (up to 7 days) to confirm eligibility, including medical history, physical exam, and lung function tests Enter a 14-day run-in period during which they take the comparator medication (budesonide/formoterol) twice daily Be randomly assigned to one of three treatment groups: CP006 Dose 1, CP006 Dose 2, or the comparator Take their assigned treatment twice daily for 28 days Visit the clinic at Day 0 (baseline), Day 8, Day 15, and Day 29 for lung function tests, safety checks, and questionnaires (ACQ-5 and AQLQ) Measure their morning and evening peak expiratory flow (PEF) daily using a handheld device and record the results in a diary Return for a follow-up safety visit or phone call at Day 43 (±2 days) The total duration of participation is approximately 58 to 65 days.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Budesonide
  • Formoterol
  • Umeclidinium
  • Inhalation Powder
  • Triple Therapy
  • Phase II
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Ability to understand and comply with study procedures, willing to complete the study as per protocol, and provide written informed consent.
  2. Age 18 to 75 years (inclusive), both sexes, BMI \< 40 kg/m².
  3. Diagnosis of bronchial asthma per Chinese Guidelines for the Prevention and Management of Asthma (2024 edition) with documented medical history ≥ 3 months, and currently inadequately controlled asthma as defined by ACQ-5 score ≥ 1.5.
  4. Regular daily use of medium/high-dose ICS/LABA regimen (including stable ICS dose) for at least 4 weeks prior to Visit 1.
  5. Non-smoker, or smoking cessation for at least 6 months (including cigarettes, cigars, pipe tobacco), with smoking history ≤ 30 pack-years.
  6. Positive bronchodilator reversibility test within 1 year prior to screening; or, if not available, meet the reversibility criteria of FEV₁ increase ≥ 12% and absolute increase ≥ 200 mL during screening.
  7. Pre-bronchodilator FEV₁ ≥ 40% and ≤ 85% of predicted normal value at screening.
  8. Agree to have no fertility plan (including sperm or egg donation) and voluntarily use effective contraception (including partner) during the study and for 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Allergy to any sympathomimetic amines (e.g., formoterol or salbutamol), glucocorticoids, or excipient lactose.
  2. Life-threatening asthma, defined as asthma exacerbation requiring non-invasive/invasive mechanical ventilation, and/or history of hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncope within 1 year prior to screening or during run-in.
  3. Acute upper or lower respiratory bacterial infection requiring systemic antibiotic therapy within 4 weeks prior to screening or during run-in, which leads to changes in asthma treatment or may affect study participation per investigator's judgment.
  4. Concurrent respiratory diseases other than asthma, including but not limited to idiopathic pulmonary fibrosis, clinically significant atelectasis, active tuberculosis, COPD, bronchiectasis, etc., which may place the subject at undue risk or affect study outcome assessment per investigator's judgment.
  5. History of malignancy in any organ system within the past 5 years, except for early-stage tumors with low metastatic and mortality risk that have been curatively treated.
  6. Severe cardiovascular disease, including but not limited to NYHA Class III-IV, severe arrhythmias such as QTcF prolongation (QTcF > 450 ms for males, > 460 ms for females), myocardial infarction or unstable angina within 6 months prior to screening, or poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on 2 or more consecutive measurements).
  7. Hepatic or renal impairment defined as ALT > 2×ULN, AST > 2×ULN, or serum creatinine > 1.5×ULN.
  8. History of familial hypokalemia or conditions predisposing to severe hypokalemia, or serum potassium below the lower limit of normal at screening.
  9. Current or history of glaucoma, cataract, symptomatic prostatic hypertrophy, urinary retention, or bladder neck obstruction.
  10. Poorly controlled diabetes mellitus (fasting blood glucose > 10 mmol/L on 2 consecutive non-fasting days or HbA1c ≥ 8.0%).
  11. History of drug abuse, substance abuse, or alcohol abuse within 1 year prior to screening (alcohol abuse defined as average daily alcohol intake > 2 units; 1 unit = 360 mL beer, or 45 mL of 40% liquor, or 150 mL wine).
  12. Use of inhaled short-acting anticholinergics, inhaled short-acting β₂-agonists (other than study drug), or combinations thereof within 24 hours prior to screening.
  13. Use of LAMA or LAMA-containing combination products within 4 weeks prior to screening.
  14. Use of any marketed or investigational biologic agents for asthma (e.g., omalizumab, mepolizumab, benralizumab, reslizumab) within 3 months or 5 half-lives (whichever is longer) prior to screening.
  15. Use of theophyllines, oral sustained-release bronchodilators, antihistamines, or anti-allergic drugs for asthma within 1 week prior to screening.
  16. Use of anti-leukotriene agents within 48 hours prior to screening.
  17. Use of tricyclic antidepressants, MAOIs, or SSRIs (e.g., fluoxetine, sertraline) within 4 weeks prior to screening, except for stable SSRI use for at least 4 weeks prior to screening.
  18. Use of CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) within 2 weeks prior to screening.
  19. Use of systemic corticosteroids at a dose ≥ 20 mg/day prednisone or equivalent for more than 1 week within 4 weeks prior to screening, or use of systemic corticosteroids at ≥ 20 mg/day prednisone or equivalent within 1 week prior to screening.
  20. Initiation of allergen immunotherapy within 4 weeks prior to screening, except for those who have been on stable-dose treatment for at least 4 weeks prior to screening and will maintain stable dose during the study.
  21. Oral candidiasis suspected or confirmed by investigator on oral examination.
  22. Participation in another clinical trial and receipt of investigational drug/treatment within 2 months prior to enrollment.
  23. Pregnant or lactating females, or positive pregnancy test in women of childbearing potential.
  24. Any other condition that, per investigator's judgment, may affect the assessment of efficacy or safety, or makes the subject unsuitable for enrollment.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    CP006 Dose 1 (BUD/FORM/UMEC 390/11/55 μg/day)

    Participants receive CP006 Inhalation Powder (budesonide/formoterol/umeclidinium) at 195 μg/5.5 μg/27.5 μg per inhalation, 1 inhalation twice daily (total daily dose 390 μg/11 μg/55 μg), for 28 days. Also receive placebo matching the comparator to maintain blinding.

    Drug: Budesonide, Formoterol Fumarate, and Umeclidinium Bromide · Drug: Placebo for Budesonide and Formoterol Fumarate · Drug: Albuterol Sulfate

  • Experimental
    CP006 Dose 2 (BUD/FORM/UMEC 390/11/27.5 μg/day)

    Participants receive CP006 Inhalation Powder (budesonide/formoterol/umeclidinium) at 195 μg/5.5 μg/13.8 μg per inhalation, 1 inhalation twice daily (total daily dose 390 μg/11 μg/27.5 μg), for 28 days. Also receive placebo matching the comparator to maintain blinding.

    Drug: Budesonide, Formoterol Fumarate, and Umeclidinium Bromide · Drug: Placebo for Budesonide and Formoterol Fumarate · Drug: Albuterol Sulfate

  • Active comparator
    Active Comparator (BUD/FORM 640/18 μg/day)

    Participants receive budesonide/formoterol inhalation powder (Symbicort® Turbuhaler®) at 160 μg/4.5 μg per inhalation, 2 inhalations twice daily (total daily dose 640 μg/18 μg), for 28 days. Also receive placebo matching the investigational drug to maintain blinding.

    Drug: Budesonide and Formoterol Fumarate · Drug: Placebo for CP006 Inhalation Powder · Drug: Albuterol Sulfate

Interventions

  • DrugBudesonide, Formoterol Fumarate, and Umeclidinium Bromide

    CP006 Inhalation Powder, 195 μg/5.5 μg/27.5 μg per inhalation. Administered as 1 inhalation twice daily for 28 days. Contains budesonide 195 μg, formoterol fumarate 5.5 μg, and umeclidinium bromide (equivalent to umeclidinium 27.5 μg) per inhalation.

    Also known as: CP006 Inhalation Powder (High Dose: 195/5.5/27.5 µg)

  • DrugBudesonide, Formoterol Fumarate, and Umeclidinium Bromide

    CP006 Inhalation Powder, 195 μg/5.5 μg/13.8 μg per inhalation. Administered as 1 inhalation twice daily for 28 days. Contains budesonide 195 μg, formoterol fumarate 5.5 μg, and umeclidinium bromide (equivalent to umeclidinium 13.8 μg) per inhalation.

    Also known as: CP006 Inhalation Powder (Low Dose: 195/5.5/13.8 µg)

  • DrugBudesonide and Formoterol Fumarate

    Budesonide and formoterol fumarate inhalation powder (Symbicort® Turbuhaler®), 160 μg/4.5 μg per inhalation. Administered as 2 inhalations twice daily for 28 days.

    Also known as: Symbicort® Turbuhaler®

  • DrugPlacebo for CP006 Inhalation Powder

    Placebo matching CP006 Inhalation Powder. Contains no active pharmaceutical ingredients. Administered as 1 inhalation twice daily for 28 days to maintain blinding.

  • DrugPlacebo for Budesonide and Formoterol Fumarate

    Placebo matching budesonide and formoterol fumarate inhalation powder (Symbicort® Turbuhaler®). Contains no active pharmaceutical ingredients. Administered as 2 inhalations twice daily for 28 days to maintain blinding.

  • DrugAlbuterol Sulfate

    Albuterol sulfate inhalation aerosol (Ventolin®), 100 μg per actuation. Used as rescue medication on an as-needed basis for asthma symptoms during the run-in and treatment periods.

05

What researchers measure

Primary outcomes

  1. Change from Baseline in Morning Pre-dose Trough FEV₁ at Day 29

    Forced expiratory volume in one second (FEV₁) measured before the morning dose of study medication (after at least 12 hours since the last dose) at Day 29. Change from baseline is calculated as the Day 29 value minus the baseline value (measured at Day 0 before the first dose).

    Time frame: Baseline (Day 0) and Day 29

Secondary outcomes

  1. Change from Baseline in Morning Pre-dose Trough FEV₁ at Day 8 and Day 15

    Forced expiratory volume in one second (FEV₁) measured before the morning dose of study medication at Day 8 and Day 15. Change from baseline is calculated as the value at each time point minus the baseline value (measured at Day 0 before the first dose).

    Time frame: Baseline (Day 0), Day 8, and Day 15

  2. Change from Baseline in Mean Morning and Evening Pre-dose PEF at Day 7, Day 14, and Day 28

    Peak expiratory flow (PEF) measured by a handheld peak flow meter before the morning and evening doses of study medication. The mean PEF value over the 7 days prior to each visit is calculated. Change from baseline is calculated as the mean value at each time point minus the baseline mean value (measured during the 7 days prior to randomization).

    Time frame: Baseline (7 days prior to randomization), Day 7, Day 14, and Day 28

  3. Change from Baseline in Mean Daily PEF Diurnal Variability at Week 4

    PEF diurnal variability is calculated as 2 × (highest PEF in a day - lowest PEF in a day) / (highest PEF in a day + lowest PEF in a day) × 100%. The mean daily PEF diurnal variability over 7 days at Week 4 is compared to baseline (the 7 days prior to randomization).

    Time frame: Baseline (7 days prior to randomization) and Week 4

  4. Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score at Day 15 and Day 29

    The AQLQ consists of 32 items covering symptoms, activity limitation, emotional function, and environmental stimuli. Each item is scored on a 7-point scale (1 = severely impaired, 7 = not impaired at all). The total score is the mean of all item scores. Change from baseline is calculated as the score at each time point minus the baseline score (measured at Day 0 before the first dose).

    Time frame: Baseline (Day 0), Day 15, and Day 29

  5. Change from Baseline in Asthma Control Questionnaire (ACQ-5) Score at Day 8, Day 15, and Day 29

    The ACQ-5 consists of 5 questions assessing asthma symptoms, rescue medication use, and impact on daily activities over the past week. Each item is scored on a 0-6 scale. The total score is the mean of all item scores. Change from baseline is calculated as the score at each time point minus the baseline score (measured at Day 0 before the first dose).

    Time frame: Baseline (Day 0), Day 8, Day 15, and Day 29

  6. Total Number of Actuations of Rescue Medication Used During the Treatment Period

    Total actuations of albuterol sulfate inhalation aerosol (100 µg per actuation) used on an as-needed basis for asthma symptoms during the 28-day treatment period.

    Time frame: Day 1 through Day 28

  7. Total Number of Days with Rescue Medication Use During the Treatment Period

    Number of days on which albuterol sulfate inhalation aerosol was used at least once during the 28-day treatment period.

    Time frame: Day 1 through Day 28

  8. Percentage of Days with No Rescue Medication Use During the Treatment Period

    Percentage of days during the 28-day treatment period on which no albuterol sulfate inhalation aerosol was used, calculated as (number of days with no rescue medication use / total days in the treatment period) × 100%.

    Time frame: Day 1 through Day 28

  9. Time to First Asthma Exacerbation During the Treatment Period

    Time from randomization (Day 0) to the first occurrence of an asthma exacerbation, measured in days.

    Time frame: Day 0 through Day 28

  10. Number of Participants with Moderate Asthma Exacerbations

    Number of participants who experienced at least one moderate asthma exacerbation during the 28-day treatment period.

    Time frame: Day 1 through Day 28

  11. Number of Participants with Severe Asthma Exacerbations

    Number of participants who experienced at least one severe asthma exacerbation during the 28-day treatment period.

    Time frame: Day 1 through Day 28

06

Study locations

13 sites
  • Hefei First People's Hospital
    Hefei, Anhui 230061, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Chongqing Fuling Central Hospital
    Chongqing, Chongqing Municipality 408099, China
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050031, China
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
  • Huai'an First People's Hospital
    Huai'an, Jiangsu 223300, China
  • Lianyungang First People's Hospital
    Lianyungang, Jiangsu 222002, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
  • Yan'an University Xianyang Hospital
    Xianyang, Shaanxi 712000, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Zhongjiang People's Hospital
    Kaijiang, Sichuan 618100, China
  • Mianyang Central Hospital
    Mianyang, Sichuan 621099, China
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The informed consent obtained from participants in this study did not include provisions for the sharing of individual participant data with third parties or for the transfer of data outside of China. Sharing IPD would therefore be inconsistent with the scope of the consent provided by participants and with applicable data protection requirements. Requests for the study protocol and statistical analysis plan may be directed to the sponsor at clinicalmedicine@chenpon.com and will be considered on a case-by-case basis.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07807007
Lead sponsor
Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 8, 2026
Start date
Nov 21, 2025
Primary completion
Aug 3, 2026
Completion
Aug 17, 2026
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma→

Other studies from this sponsor

Shanghai Xin Huanghe Pharmaceutical Co., Ltd.

Start the discussion